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Abstract
Single-cell genetics were used to interrogate clonal complexity and the sequence of mutational events in STIL-TAL1+ T-
ALL. Single-cell multicolour FISH was used to demonstrate that the earliest detectable leukaemia subclone contained the
STIL-TAL1 fusion and copy number loss of 9p21.3 (CDKN2A/CDKN2B locus), with other copy number alterations
including loss of PTEN occurring as secondary subclonal events. In three cases, multiplex qPCR and phylogenetic analysis
were used to produce branching evolutionary trees recapitulating the snapshot history of T-ALL evolution in this leukaemia
subtype, which conﬁrmed that mutations in key T-ALL drivers, including NOTCH1 and PTEN, were subclonal and
reiterative in distinct subclones. Xenografting conﬁrmed that self-renewing or propagating cells were genetically diverse.
These data suggest that the STIL-TAL1 fusion is a likely founder or truncal event. Therapies targeting the TAL1 auto-
regulatory complex are worthy of further investigation in T-ALL.
Introduction
Single-cell genetics in haematopoietic [1–3] and other
cancers [4, 5] have revealed substantial intraclonal com-
plexity. In general, this diversity reﬂects evolutionary
phylogenies with derivative subclones branching off from
founder precursors [6]. Architectural population diversity in
cancer has important implications for reservoirs of cells
involved in progression of disease and drug resistance
therapy. Bioinformatic derivations of evolutionary trees can
reveal the most likely sequence of genetic events and dis-
tinguish mutations that are present in all cancer cells, as
truncal or founder events, versus those that are secondary
and subclonally distributed [7–9]. This in turn carries
implications for minimal residual disease (MRD) monitor-
ing and targeted therapy.
Few such studies have been performed to date in T-ALL,
although comparative genetic proﬁling of diagnostic,
xenograft and relapse samples conﬁrms clonal complexity
[10, 11]. T-ALL is biologically diverse reﬂecting levels of
differentiation arrest within the thymus and distinctive
genetic lesions [12]. We elected to study a single, common
subtype of T-ALL, namely those with STIL-TAL1 fusion.
We used multicolour FISH and single-cell multiplex
quantitative-PCR (qPCR) to determine the phylogenetic
architecture of diagnostic samples and to infer the order of
genetic events comparing STIL-TAL1 fusion, which we
postulated as a founder lesion, with other common genetic
lesions including CDKN2A loss, PTEN mutation or loss and
NOTCH1 mutation. In selected cases, we compared the
clonal architecture of xenotransplanted samples with that
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observed in the diagnostic sample. This enabled us to infer
the subclonal origins and genetic diversity of cells with
propagating or stem cell activity.
Materials and methods
Patient samples
Diagnostic DNA of 19 T-ALL cases aged 1–24 years and 1
cell line (RPMI 8402) known to have the STIL-TAL1 rear-
rangement were available. The study was conducted in
accordance with the Declaration of Helsinki and appropriate
consent and ethical approval for the study was obtained
(Ethics approval numbers CCR2285 and 16/SE/0219).
T-ALL molecular screening and cloning
Diagnostic DNA from all STIL-TAL1 cases was analysed
for mutations in known T-ALL mutational hotspots in
NOTCH1 (exons 26, 27 and 34), FBXW7 (exons 9 and 10),
PTEN (exon 7) and IL7R (exon 6) using previously pub-
lished methods [13–16]. All diagnostic samples were
analysed by SNP-array to identify genomic losses and
gains using the Affymetrix SNP 6.0 platform. Genotyping
and generation of QC data were performed in Genotyping
ConsoleTM v4.1.4 software (Affymetrix). CNAG version
3.3.0.1 beta was used to normalise output to a self-
reference (patient remission DNA) or via a batch pairwise
analysis using sex-matched control samples. The STIL-
TAL1 patient-speciﬁc gene fusion was sequenced for the
three cases that underwent single-cell genotyping analyses
using previously published methods [17]. The TA Cloning
Kit® (Invitrogen by Life TechnologiesTM) was used for
cloning experiments according to the manufacturer’s
instructions.
Next-generation sequencing (NGS)
Whole exome sequencing (WES) was undertaken by
Oxford Gene Technology. See Supplementary Methods for
details and bioinformatics. Any genomic ‘drivers’ included
in the single-cell genotyping experiments were validated
with Sanger sequencing using custom primers designed
using Primer Blast (Table S1).
Fluorescence in situ hybridisation
Fixed cytospins were prepared from archived viable cells
and interphase FISH was performed with patient-speciﬁc
FISH probes for the various copy number losses using in-
house FISH probes (Table S2) and previously described
methods [18]. See Supplementary Methods for details.
Bioinformatic assessment of RAG recombinase
activity at PTEN indel breakpoints
MEME Suite 4.11.4 [19] was used to conduct an agnostic
search for the RAG recombinase consensus heptamer and
nonamer and also for the tetramer sequence (CACA)
identiﬁed [20] as being recurrently present at RAG-
mediated breakpoint sequences. We also used a weighted
matrix algorithm (code availability—script kindly provided
by the laboratory of Dr Papaemmanuil) to generate RAG
recombination signal sequences (RSS) scores for each
deletion breakpoint of interest. Essentially, this ascribed a
likelihood score or weight to each base pair in the putative
heptamer-spacer-nonamer sequence of interest according to
the likelihood of deviation from consensus based on what
the base pair is for the heptamer/nonamer and the number of
bases rather than base choice per se for the spacer (score
details outlined in ref. [21]).
Single-cell genotyping and single-cell Sanger
sequencing
Single-cell genetic analysis was performed using stored
viable cells for cases CUL76, 6116 and 6030 and paired
xenograft material. Our previously established multiplex
qPCR approach was used [2] with minor modiﬁcations.
See Supplementary Methods for details.
Xenograft material
Limited archived xenograft DNA and single-cell material
prepared from xenograft bone marrow was available on
samples CUL76, 6030 and 6116. Material generated using
NOG (NOG-ShiSCID-IL2gamma null) mice was available
for samples 6030 and 6116 and using NRG (NOD-Rag1null
IL2rgnull, NOD rag gamma) mice for sample CUL76. In all
cases, 1 × 106 cells were injected and experiments were
performed on material stored from primary passage bone
marrow.
Results
Molecular screening on STIL-TAL1+ T-ALL samples
for recurrent drivers
Nineteen STIL-TAL1+ cases and one cell line were
screened for common genetic rearrangements using copy
number proﬁling and Sanger sequencing. Data on Brazilian
samples BR75, BR74, S1 and S2 have been previously
published [22, 23]. Four cases also underwent WES to
identify both known driver targets for inclusion in single-
cell experiments and novel drivers. Results of molecular
C. L. Furness et al.
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The subclonal complexity of STIL-TAL1+ T-cell acute lymphobl…
screening are summarised in Table 1 (further details avail-
able from Tables S8, S9 and S10). Mean target coverage
across the samples (and paired remission samples) that
underwent WES was 95×–126× (average 109×). Total of
7–10 protein altering SNVs and 3–5 protein altering indels
(detectable at a read depth >20) were detected per sample
(Tables S11 and S12). All drivers incorporated in to single-
cell experiments were validated with qPCR or Sanger
sequencing.
In keeping with previous work highlighting that cases
from the TAL/LMO gene expression subgroup tend to have
a higher incidence of PTEN mutations and a lower inci-
dence of NOTCH1 mutations [24], within our cohort of 20
patients (combining PTEN inactivation due to exon 7
mutation or copy number loss) we detected a frequency of
PTEN inactivation of at least 40% (around double the
frequency of PTEN inactivation (22%) detected in a recent
study of 145 T-ALL cases using heteroduplex analysis,
mutations and SNP arrays) [25]. Additionally in the cases
that underwent WES, mutations in PTEN outside the
hotspot of exon 7 were detected (exon 8 in sample 6030
and exon 5 in CF10), suggesting that estimates based on
copy number analysis and PTEN exon 7 sequencing may
be an underestimate. A high frequency of copy number
losses of 9p (95%, incorporating CDKN2A/CDKN2B
locus) and 6q (30%) was also observed and these were
identiﬁed as key drivers to include in single-cell geno-
typing studies.
Exome sequencing of four cases deﬁned relevant
known and potential T-ALL drivers to include in single-
cell analysis experiments. Novel T-ALL potential drivers
were detected: mutations in BMPR1A, FREM2 and
PIK3CD. BMPR1A (bone morphogenetic protein receptor,
type 1A) is a polyposis associated gene—a type 1A
transmembrane serine/threonine kinase listed in the cosmic
cancer gene census of genes functionally linked to cancer
and PIK3CD is a subunit of phosphatidylinositol-4,5-
bisphosphate 3-kinase a key member of the PTEN-PI3
kinase pathway. Both 6030 and 6116 contained one
mutation per sample in FREM2 and one of these mutations
(found re-iteratively in sample 6116) is found in the cos-
mic database as a somatic mutation in a GI carcinoma
(COSM287123). Additionally, this gene was recurrently
but non-signiﬁcantly mutated in three T-ALL samples in a
large exome T-ALL sequencing study [26]. The gene
encodes an integral membrane protein containing many
chondroitin sulphate proteoglycan element repeats and
calx-beta domains (although the identiﬁed mutations lie
outside these domains, Figure S3). In view of the possible
association with T-ALL, and the emerging role of the
micro-environment/extracellular matrix in leukaemia and
cancer, we included FREM2 mutations in our single-cell
studies.
Reiterative inactivation of PTEN
Sanger sequencing and NGS data for samples 6030 and
CF5 suggested the presence of multiple low-level PTEN
exon 7 indels running in parallel (Fig. 1a, b). Parallel work
by a collaborating group using HPLC wave technology
(heteroduplex analysis) [25] also led to similar conclusions.
Cloning experiments validated at least four independent
indels for sample 6030. Sample CF10 also had two PTEN
indels in exons 5 and 7 (detected by WES and Sanger
sequencing). The multiple PTEN indels resulted function-
ally in the generation of stop codons in all but one of the
mutations analysed (10/11; Table S13). Given the striking
reiterative inactivation of PTEN, we hypothesised that these
small structural alterations could be RAG-mediated given
the involvement of aberrant RAG in the formation of the
STIL-TAL1 fusion and CDKN2A deletions and the obser-
vation that RSS elsewhere in PTEN have been implicated in
the formation of small microdeletions [27]. However, we
did not ﬁnd bioinformatic evidence to support this expla-
nation with maximum RSS scores of 6.75 (Table S14)
compared to >8.55 in B cell precursor (BCP)-ALL samples
using the same weighted matrix algorithm [20]. Only one
sample (CF10) had the RAG-associated CACA tetramer
identiﬁed in Papaemmanuil et al. (2014) close to the
mutation breakpoint.
Single-cell studies in STIL-TAL1+ T-ALL
Multicolour FISH
We investigated the order of acquisition of CNAs with
reference to the STIL-TAL1 fusion in samples 6030, CF5,
CF6 and HK328. In the majority of cases, the earliest
ancestor subclone contained the STIL-TAL1 fusion in
combination with bi-allelic loss of 9p21.3 (containing
CDKN2A locus) as shown for samples CF5 and CF6
(Fig. 2). In contrast with BCP-ALL [9] in the majority of
cases 9p21.3 could not be separated in time from the pre-
sumed founder gene fusion/translocation. Additional copy
number losses including 6q and PTEN occurred in a sec-
ondary and subclonal fashion. However, in sample 6030 the
earliest detectable subclone contained STIL-TAL1+ cells
with 1 copy of 9p21.3. This observation was validated using
two independent FISH probes and the clone was also
detected in xenograft bone marrow derived from sample
6030 (Figure S1a).
Single-cell multiplex qPCR
Although multicolour FISH provides proof-of-principle
evidence for clonal heterogeneity in T-ALL, the number
of driver genetic events that can be examined is limited and
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mutations in key T-ALL signalling pathways cannot be
incorporated. We undertook a detailed single-cell genotyp-
ing study on three samples that represented all the key STIL-
TAL1 genetic driver events identiﬁed in this study and
which had archived paired xenograft material available.
Archived diagnostic leukaemia cells from cases 6030, 6116
and CUL76 underwent high-throughput single-cell multi-
plex qPCR analysis allowing simultaneous investigation of
the patient-speciﬁc STIL-TAL1 gene fusion in each case
along with indels, SNVs and CNA designated driver status
for each leukaemia sample. Quality control assessments and
analysis were performed as previously described [2].
Phylogenetic trees for these three diagnostic cases
constructed from single-cell data using the principle of
maximum parsimony are shown in Fig. 3a–c. In all cases
the root of the tree contains a common ancestor cell con-
taining the patient-speciﬁc STIL-TAL1 fusion and copy
number loss of CDKN2A. Other key drivers are subclonal
but in some cases re-iterative in keeping with observations
made in prior studies of B cell leukaemias and solid
tumours [2, 9, 28–30]. The STIL-TAL1 assays used were
speciﬁc for the patient-speciﬁc fusions (Table S15) and
tested against both normal DNA and other STIL-TAL1
positive material to conﬁrm assay speciﬁcity. This study
provides the ﬁrst evidence that a single STIL-TAL1 fusion
occurs per case (previous studies assessing stability
through xenograft passage have used chromosome 1p copy
number as a surrogate for the gene fusion but this would
not differentiate the presence of multiple overlapping
fusions with relatively conserved mutation breakpoint
region). NOTCH1 mutation and PTEN mutation are sec-
ondary and subclonal events in the case studies. The
multiple PTEN mutations noted in sample 6030 were
tracked at single-cell level and single-cell cloning and
Sanger sequencing were used to demonstrate unequi-
vocally that in clones with >1 mutation, mutations
occurred on independent alleles suggesting a selective
pressure for bi-allelic inactivation of PTEN (Fig. 1c).
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Fig. 1 Reiterative bi-allelic deletion of PTEN. a Multiplex qPCR data
show that PTEN indels 2 and 3 are localised within the same single
cells. The coloured boxes at the junction between the vertical qPCR
assays (run in duplicates) and the horizontal individual cells represent
mutation-speciﬁc ampliﬁcation with the colour of each box correlating
with the level of ampliﬁcation (raw Ct value). Black represents no
ampliﬁcation. b Reiterative PTEN exon 7 indel mutations are seen
within the raw data reads of whole exome sequencing data for sample
6030. c Cloning of PTEN exon 7 from representative single cells
demonstrated that these indels are present on separate alleles as one
single-cell clone contains indel 2 but is wild-type (WT) for indel 3,
whereas another single-cell clone contains indel 3 but is WT for indel
2 demonstrating bi-allelic inactivation of PTEN. Cell number 17 refers
to experimental single-cell DNA plate position
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The use of xenograft models can be used to assess clonal
heterogeneity and evolution in the leukaemia initiating or so
called ‘cancer stem-cell’ compartment providing insight in
to genetic driver stability and evolutionary pressures on
clonal selection. Single-cell assessment of xenograft bone
marrow in the three cases examined demonstrated con-
trasting models of clonal evolution, although it is
acknowledged that limited conclusions can be drawn from
the single xenograft per case experiments performed.
Clones that read-out in the xenograft are designated ‘T’
status in the evolutionary tree diagrams (Fig. 3a–c). In cases
6116 and CUL76, multiple clones read out in the xenograft
conﬁrming the position of NOTCH1 as a subclonal driver
and demonstrating multiple competing subclones in the
leukaemia initiating cell compartment. However, in case
6030 a single dominant clone (C7) predominated containing
the STIL-TAL1 fusion, bi-allelic 9p21.3 deletion and a
PTEN exon 8 mutation, which was present in both hetero-
zygous and homozygous form. The proportion of cells
within this subclone with a homozygous (as opposed to
heterozygous) PTEN exon 8 mutation was higher in the
xenograft than the diagnostic sample (88% versus 47%) and
all xenograft single cells had either the heterozygous or
homozygous mutation (i.e., no PTEN exon 8 wild-type cells
detected based on Sanger sequencing of 78 single cells).
The clones with PTEN exon 7 mutations were not detected
in the xenograft. This validated bulk DNA sequencing data
from the xenograft material which demonstrated the
homozygous PTEN exon 8 mutation and wild-type PTEN
exon 7 analysis (data not shown).
Comparison of 6030 xenograft single-cell FISH and
multiplex qPCR data initially appeared to generate con-
ﬂicting results with FISH data suggesting the presence of a
clone with 1 copy of 9p21.3 in both diagnostic and xeno-
graft material but single-cell data demonstrating bi-allelic
loss in all subclones. Examination of SNP copy number
data resolved this discrepancy, which was due to one of the
9p21.3 deletions being smaller than the size of the FISH
probe so that the FISH subclone containing ‘1 copy’ of
9p21.3, 2 copies of 4p/6q (Figure S1a) actually
Normal Cell
(4%) 
ST F
0 CDKN2A
2 PTEN
(55.7%)
ST F
0 CDKN2A
1 PTEN
(40.3%)
Sample CF5
Normal Cell
(22.3%)
ST F
0 CDKN2A
2 PTEN
(3.1%)
ST F
0 CDKN2A
1 PTEN
(74.6%)
Sample CF6
FISH Probes
STIL-TAL1 sub-deletion probe
CDKN2A
PTEN
Fig. 2 Multicolour FISH in STIL-TAL1 T-ALL. Examples for evolu-
tionary trees for samples CF5 and CF6 are shown. Percentages
represent the frequency of each subclone as assessed by single-cell
multicolour FISH with circle size representing relative frequencies.
Photos shown are from sample CF5 using the following FISH probes:
STIL-TAL1 (labelled spectrum red-spectrum green); p16.1 as a marker
of CDKN2A loss (labelled Cy3, coloured blue in diagram); PTEN
(labelled Biotin-Cy5, coloured pink in diagram). Note the STIL-TAL1
FISH probe is a subdeletion probe. Normal cells have two co-localised
red-green signals. Cells with the STIL-TAL1 fusion due to 1p33
deletion lose one red signal while retaining the control green signal. ST
F: STIL-TAL1 Fusion. Numbers (0, 1, 2) next to gene name (PTEN or
CDKN2A) represent copy number results by FISH, e.g., 2 PTEN, two
copies of PTEN, 0 CDKN2A, zero copies of CDKN2A
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corresponded to clone C7 in multiplex qPCR data (Fig. 3c),
i.e., CDKN2A actually demonstrated bi-allelic deletion
when small qPCR assays were used to assess copy number
status. Examination of paired diagnosis/xenograft copy
number data for case 6030 also demonstrated that CDKN2A
loss is a subclonal event as with regard to the loss of the
second allele of CDKN2A at least two independent clones
had emerged with distinct breakpoints (Figure S1b). Since
ba
I                                                              II
c
67LUCelpmaS6116elpmaS
Sample 6030
Fig. 3 a–c Single-cell multiplex qPCR evolutionary analysis samples
6030, 6116 and CUL76. Evolutionary trees generated by bioinfor-
matics analysis of single-cell data are shown. Gene names of drivers
tracked are shown next to the subclones. Presence of a gene name
indicates gene mutation present in the case of SNVs or indels. Where
the driver is a deletion number of copies of gene present (0 or 1) is
shown. Yellow circles represent leukaemic subclones and a black
circle and the N label indicates the normal state. The size of the circle
is proportional to the number of cells in each subclone and the detected
genetic markers are listed below each circle. Red T= subclones that
read-out in xenotransplants (detailed xenograft single-cell data in
Supplementary Table 16). Grey boxes represent inferred subclones;
these are groups of cells, which have died out, been outcompeted or if
still present, exist at low frequencies below the level of reliable
detection using this approach. Tree branch lengths are directly pro-
portional to the number of evolutionary changes inferred and the
points at which the branches diverge (nodes) represent the ancestor
state of a clonal clade; a monophyletic group, which includes all
descendants of the ancestor. The number in grey colour at each node
indicates the bootstrap value. The phylogeny shows how the clonal
expansion has evolved from a common ancestor toward the observed
states. Note that for case CUL76 as a limited number of drivers were
tracked based on mutation screening and copy number data another
known mutation present in this sample (SORC3, passenger mutation)
was included to aid assessment of clonal structure. a Case 6116 (N=
308 cells). The root of the tree harbours the STIL-TAL1 fusion (F) and
a homozygous CDKN2A deletion. Two equally parsimonious trees (I
and II) are generated which differ as to whether the FREM2 or
PIK3CD mutated clone gives rise to the latest detectable C4 clone. The
NOTCH1 mutation is a subclonal event. b CUL76 (N= 151 cells). The
root of the tree harbours the STIL-TAL1 F and a homozygous
CDKN2A deletion and a LMO2 deletion in this case. PTEN inactiva-
tion, through copy number loss, and NOTCH1 mutation are subclonal.
The NOTCH1 TAD domain exon 34 mutation was only detected in
clone C2 (NOTCH1 mutation status determined by single-cell Sanger
sequencing of 44 single cells). The pie chart shows the proportions of
C2 subclone cells that are either wild-type (WT) or NOTCH1 mutated.
c 6030 (N= 216 cells). The root of the tree harbours the STIL-TAL1 F
and a homozygous CDKN2A deletion. PTEN mutations are subclonal
and re-iterative (3 PTEN indels in exon 7—labelled PTEN indels 1, 2
and 3 plus one PTEN indel in exon 8). The C6 subclone contains two
independent PTEN exon 7 mutations. PTEN exon 8 mutation was only
detected in clone C7 (PTEN exon 8 mutation status determined by
single-cell Sanger sequencing of 37 single cells). The pie chart shows
the proportions of C7 subclone cells that are WT, heterozygous PTEN
exon mutated or homozygous PTEN exon 8 mutated
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multiplex qPCR data for CDKN2A was based on copy
number assays, it is possible that multiple CDKN2A dele-
tions may exist in any one sample, which would not be
detected using the analysis method used.
Discussion
These single-cell genetic analyses allow us to infer phylo-
genetic trees describing clonal evolution. Technical limita-
tions mean that interpretation of these data carries the caveat
that we will have under-estimated clonal complexity. Our
genetic markers are also limited. More genetically distinct
subclones will exist than we currently detect. For case 6116
due to the limited genetic markers used we were unable to
determine whether the re-iterative mutation event was
PIK3CD or FREM2 mutation but did validate the bioin-
formatic analysis with single-cell Sanger sequencing ana-
lysis of FREM2 and PIK3CD mutation in single cells of the
diagnostic and xenograft samples to conﬁrm that re-iterative
mutation had occurred (Figure S2).
Despite these caveats, several informative conclusions
can be drawn. A consistent feature is that STIL-TAL1 fusion
and CDKN2A loss are both early or truncal events, in
contrast to other recurrent genetic changes including
NOTCH1 and PTEN mutation that are secondary and sub-
clonal. These observations have implications for selection
of mutations for minimal residual disease tracking and as
targets for therapy. Given the position of the STIL-TAL1
fusion in leukaemia evolution, therapies targeting the TAL1
regulatory complex [31] are worthy of further investigation.
It is difﬁcult to discern from our study whether STIL-
TAL1 or CDKN2A loss is an initiating event, or which
comes ﬁrst. The most ancestral cell in the phylogenetic
structure has STIL-TAL1 fusion plus loss of both CDKN2A
alleles. However, the latter are distinctive and presumed
independent events, but only one clone-speciﬁc STIL-TAL1
fusion exists. This ﬁnding suggests that at least one of the
CDKN2A allele deletions occurs subsequent to STIL-TAL1
fusion. This is in keeping with previously published work
demonstrating reiterative CDKN2A deletions in STIL-TAL1
cases when breakpoints of 9p21.3 deletions in paired
diagnostic/xenograft/relapse material were examined [11].
We note that both STIL-TAL1 fusion and CDKN2A loss are
likely to involve ‘off target’ RAG-dependent mutational
mechanisms.
The clonal architectures in STIL-TAL1+ ALL cases
(Fig. 3) for which we had genome sequencing data showed
branching structure as previously described in B cell pre-
cursor ALL [9]. To some extent, this is driven by reiterative
mutations of the same driver genes and resultant parallel
clonal evolution. This is evident with several driver genes
but most clearly with PTEN in patient 6030 (Fig. 3c).
Cloning these multiple mutations from single cells con-
ﬁrmed their uniqueness (Fig. 1c). In BCP-ALL, reiterative
copy number changes (e.g., in ETV6, PAX5, CDKN2A or
BTG1) are the consequence of RAG-mediated mutation,
followed by selection [9, 20, 30]. We found no bioinfor-
matics support for RAG involvement in the PTEN muta-
tions we identiﬁed. We note, however, that RSS for RAGs
have been previously implicated in PTEN small, micro-
deletions [27]. Irrespective of the mutational mechanisms
involved in these PTEN mutations, we conclude that in
STIL-TAL1 ALL there is a strong selective pressure for
these genetic lesions, most likely related to epistasis or a
strong functional complementarity between PTEN inacti-
vation/loss, STIL-TAL1 fusion and CDKN2A loss.
The objective, in our limited xenograft studies, was to
determine the subclonal origin and genetic diversity of
propagating or self-renewing cells in STIL-TAL1+ ALL.
The data indicate that multiple subclones read out in the
mice reﬂecting, we suggest, the existence of genetically
diverse stem cells. In patient 6116 (Fig. 3a), all four
diagnostic subclones read out in the transplants and in
patient CUL76 (Fig. 3b) all three subclones. Patient 6030
gave a different result however. One dominant subclone
(subclone C7; Fig. 3c) read-out of the seven that existed
in the diagnostic sample. However, the diagnostic sub-
clone C7 was heterogeneous with respect to PTEN exon
8 status and this directly was also reﬂected in the trans-
plant read-outs, indicating that two small subclones of
clone C7 had propagated in the mice, providing further
evidence for selection favouring PTEN-mutated clones.
Genetically diverse propagating or stem cells were
similarly demonstrated in B cell precursor ALL [9, 32]
and in glioblastoma [33] and are likely to be a common
feature in cancer [34, 35]. The implication of this
observation is that multiple subclones harbour the pro-
liferative potential to fuel progression of disease, relapse
and drug resistance.
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